Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
CalciMedica, Inc. incurred credit facility of up to $32,500,000 with Avenue Venture Opportunities Fund II, L.P. at annual rate equal to the greater of (a) the sum of 5.00% plus the prime rate as maturing September 1, 2028.
- Instrument
- credit facility
- Principal
- up to $32,500,000
- Counterparty
- Avenue Venture Opportunities Fund II, L.P.
- Rate
- annual rate equal to the greater of (a) the sum of 5.00% plus the prime rate as
- Maturity
- September 1, 2028
- Event
- incurrence
Exact text from the filing
On February 28, 2025 (the “Closing Date”), CalciMedica, Inc. (the “Company”) entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund II, L.P. (the “Lender”) and Avenue Capital Management II, L.P., as administrative agent and collateral agent, for growth capital loans in an aggregate principal amount of up to $32,500,000 (the “Loan”), with (i) $10,000,000 funded on the Closing Date (“Tranche 1”), (ii) up to $7,500,000 to be made available to the Company between September 1, 2025 and March 31, 2026, subject to, among other things, the Company’s achievement of certain milestones with respect to certain of its ongoing clinical trials (“Tranche 2”) and (iii) up to $15,000,000 to be made available to the Company between October 1, 2025 and March 31, 2026, subject to, among other things, (a) the Company’s achievement of additional milestones with respect to certain of its ongoing c
View on SEC.gov